decisionhealth Newsletters, Part B News - 2006 Issue 1 (January)
Key ASP drug price changes
Subscribe or sign in to view the full article.
Article Overview
This article reviews a set of significant first-quarter 2006 payment changes under Medicare’s average sales price methodology for commonly billed injectable drugs. It is aimed at coding and reimbursement professionals who track ASP updates, payment trends, and frequently billed Part B drug claims. The piece presents broad context on which types of drugs saw the largest payment increases and decreases, along with the source and timeframe used for the comparison.
Why This Topic Matters
ASP pricing updates can affect payment expectations, claim review, and reimbursement monitoring for practices and facilities that bill injectable drugs under Medicare Part B. Understanding which drugs experienced notable quarter-to-quarter shifts helps revenue cycle and coding teams stay current with pricing changes.
What You Will Learn
- How the article frames first-quarter 2006 ASP payment changes in Medicare Part B
- Which general categories of injectable drugs experienced notable payment increases and decreases
- What comparison periods and source basis were used for the pricing review
- How the article presents pricing movement data for commonly billed drugs
Who Should Read This
- Medical coders
- Billing specialists
- Revenue cycle staff
- Practice managers
- Compliance staff
- Healthcare reimbursement analysts
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com